ArticleResearch and practice in thrombosis and haemostasis2020
Development and application of global assays of hyper- and hypofibrinolysis.
Article in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis.Journal of thrombosis and haemostasis : JTH · 2023Guideline
- Double-edged sword: flavivirus NS1 enhances human plasmin-mediated fibrinolysis while being targeted for cleavage and inactivation.The Journal of general virology · 2026Article
- The Fibrinolytic System in Bacterial Sepsis: A Comprehensive Review of Current Assessment Methods.Journal of clinical medicine · 2025Review
- Article
- Tougher clots, safer lives? Revisiting the role of factor XIII in thrombus stability and embolization risk.Research and practice in thrombosis and haemostasis · 2025Article
- Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.Blood advances · 2023Article
- Congruent identification of imbalanced fibrinolysis by 2 distinct clot lysis time assays.Research and practice in thrombosis and haemostasis · 2023Article
- Fibrinolytic potential as a risk factor for postpartum hemorrhage.Frontiers in medicine · 2023Article
- Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study.Thrombosis journal · 2022Article
- Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield.Research and practice in thrombosis and haemostasis · 2022Article
- "Going with the flow" in modeling fibrinolysis.Frontiers in cardiovascular medicine · 2022Review
- Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma.Thrombosis research · 2021Article
- Fibrinolysis and bleeding of unknown cause.Research and practice in thrombosis and haemostasis · 2021Article
- Development and Testing of Thrombolytics in Stroke.Journal of stroke · 2021Review
- Bivalirudin and Alteplase for Pulmonary Embolism Requiring Veno-Arterial Extracorporeal Membrane Oxygenation in an Adolescent.The journal of extra-corporeal technology · 2020Article
- Impaired Fibrinolysis in Patients with Isolated Aortic Stenosis is Associated with Enhanced Oxidative Stress.Journal of clinical medicine · 2020Article
- Assessing plasminogen activation potential with global fibrinolytic assays.Research and practice in thrombosis and haemostasis · 2020Article
- Development and application of global assays of hyper- and hypofibrinolysis.Research and practice in thrombosis and haemostasis · 2020Article
- Enhanced Fibrinolysis in Lung Cancer Patients: A Functional Assessment Using Lysis Slope Time and Fibrinolytic Biomarkers.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
Abstract
Numerous methods for evaluation of global fibrinolytic activity in whole blood or plasma have been proposed, with the majority based on tissue-type plasminogen activator (t-PA) addition to initiate fibrinolysis. We propose that such an approach is useful to reveal hypofibrinolysis, but t-PA concentrations should be kept to a minimum. In this paper, we describe a low-concentration t-PA plasma turbidity assay to evaluate several congenital factor deficiencies, including plasminogen activator inhibitor-1 (PAI-1) and plasminogen deficiency, as well as hemophilia A and B. In addition, we demonstrate a threshold dependency on endogenous PAI-1 levels. To assess endogenous hyperfibrinolysis, we suggest that assays that avoid t-PA addition are preferable, with assays based on euglobulin fractionation remaining a viable choice. We describe a euglobulin fraction clot lysis time (ECLT) assay with spectrophotometric readout and other modifications, and evaluate it as a tool to measure hyperfibrinolysis in inherited clotting factor deficiency states. We demonstrate that the ECLT is predominantly driven by residual amounts of PAI-1, t-PA, and α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.